101 related articles for article (PubMed ID: 31150309)
41. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.
Giulino-Roth L; O'Donohue T; Chen Z; Bartlett NL; LaCasce A; Martin-Doyle W; Barth MJ; Davies K; Blum KA; Christian B; Casulo C; Smith SM; Godfrey J; Termuhlen A; Oberley MJ; Alexander S; Weitzman S; Appel B; Mizukawa B; Svoboda J; Afify Z; Pauly M; Dave H; Gardner R; Stephens DM; Zeitler WA; Forlenza C; Levine J; Williams ME; Sima JL; Bollard CM; Leonard JP
Br J Haematol; 2017 Dec; 179(5):739-747. PubMed ID: 29082519
[TBL] [Abstract][Full Text] [Related]
42. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
[TBL] [Abstract][Full Text] [Related]
43. Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's Lymphoma.
Huntington SF; Hoag JR; Wang R; Zeidan AM; Giri S; Gore SD; Ma X; Gross CP; Davidoff AJ
J Natl Compr Canc Netw; 2019 Oct; 17(10):1194-1202. PubMed ID: 31590152
[TBL] [Abstract][Full Text] [Related]
44. Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013.
Gleeson M; Hawkes EA; Peckitt C; Wotherspoon A; Attygalle A; Sharma B; Du Y; Ethell M; Potter M; Dearden C; Horwich A; Chau I; Cunningham D
Leuk Lymphoma; 2017 Aug; 58(8):1805-1813. PubMed ID: 27931133
[TBL] [Abstract][Full Text] [Related]
45. Outcomes and effect of radiotherapy in patients with stage I or II diffuse large B-cell lymphoma: a surveillance, epidemiology, and end results analysis.
Ballonoff A; Rusthoven KE; Schwer A; McCammon R; Kavanagh B; Bassetti M; Newman F; Rabinovitch R
Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1465-71. PubMed ID: 18495371
[TBL] [Abstract][Full Text] [Related]
46. Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era.
Kumar A; Lunning MA; Zhang Z; Migliacci JC; Moskowitz CH; Zelenetz AD
Br J Haematol; 2015 Dec; 171(5):776-83. PubMed ID: 26456939
[TBL] [Abstract][Full Text] [Related]
47. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.
Kridel R; Telio D; Villa D; Sehn LH; Gerrie AS; Shenkier T; Klasa R; Slack GW; Tan K; Gascoyne RD; Connors JM; Savage KJ
Br J Haematol; 2017 Jan; 176(2):210-221. PubMed ID: 27739058
[TBL] [Abstract][Full Text] [Related]
48. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
Papageorgiou SG; Diamantopoulos P; Levidou G; Angelopoulou MK; Economopoulou P; Efthimiou A; Constantinou N; Katsigiannis A; Korkolopoulou P; Pappa V; Economopoulou C; Georgiou G; Dimou M; Tsirigotis P; Kyrtsonis MC; Kotsianidis I; Kalpadakis C; Dimopoulos MA; Beris P; Meletis J; Pangalis GA; Dervenoulas J; Panayiotidis P; Vassilakopoulos TP
Hematol Oncol; 2013 Mar; 31(1):10-7. PubMed ID: 22610484
[TBL] [Abstract][Full Text] [Related]
49. A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma.
Torka P; Patel P; Tan W; Wilding G; Bhat SA; Czuczman MS; Lee KP; Deeb G; Neppalli V; Mavis C; Wallace P; Hernandez-Ilizaliturri FJ
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e51-e60. PubMed ID: 29233743
[TBL] [Abstract][Full Text] [Related]
50. 20 years of rituximab treatment: what have we learnt?
Renner C
Future Oncol; 2019 Dec; 15(36):4119-4121. PubMed ID: 31718346
[No Abstract] [Full Text] [Related]
51. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
52. Consolidation anti-CD22 fractionated radioimmunotherapy with
Kraeber-Bodere F; Pallardy A; Maisonneuve H; Campion L; Moreau A; Soubeyran I; Le Gouill S; Tournilhac O; Daguindau E; Jardel H; Morineau N; Bouabdallah K; Gyan E; Moles MP; Gressin R; Berthou C; Sadot S; Moreau P; Deau B; Bodet-Milin C; Cazeau AL; Garin E; Salaun PY; Vuillez JP; Gouilleux-Gruart V; Barbet J; Wegener WA; Goldenberg DM; Lamy T; Soubeyran P
Lancet Haematol; 2017 Jan; 4(1):e35-e45. PubMed ID: 27964867
[TBL] [Abstract][Full Text] [Related]
53. Trofosfamide in the treatment of elderly or frail patients with diffuse large B-cell lymphoma.
Witte HM; Riecke A; Mayer T; Bartscht T; Rades D; Lehnert H; Merz H; Fetscher S; Biersack H; Gebauer N
J Cancer Res Clin Oncol; 2019 Jan; 145(1):129-136. PubMed ID: 30327940
[TBL] [Abstract][Full Text] [Related]
54. Primary Cardiac Lymphoma: A Lesson Learned from an Unsuccessful Experience.
Ito I; Nakaoka Y; Kubokawa SI; Sugane H; Kusume T; Matsuda H; Imai RI; Nishida K; Kubo T; Yamasaki N; Kitaoka H; Kawai K; Hamashige N; Doi Y
Intern Med; 2018 Dec; 57(24):3569-3574. PubMed ID: 30146560
[TBL] [Abstract][Full Text] [Related]
55. Randomized clinical trial to assess the efficacy of radiotherapy in primary mediastinal large B-lymphoma.
Avilés A; Neri N; Fernández R; Huerta-Guzmán J; Nambo MJ
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1227-31. PubMed ID: 22172907
[TBL] [Abstract][Full Text] [Related]
56. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
[TBL] [Abstract][Full Text] [Related]
57. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349
[TBL] [Abstract][Full Text] [Related]
58. Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging.
Dorth JA; Prosnitz LR; Broadwater G; Diehl LF; Beaven AW; Coleman RE; Kelsey CR
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):762-7. PubMed ID: 22420972
[TBL] [Abstract][Full Text] [Related]
59. VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.
Chang JE; Carmichael LL; Kim K; Peterson C; Yang DT; Traynor AM; Werndli JE; Huie MS; McFarland TA; Volk M; Blank J; Callander NS; Longo WL; Kahl BS
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e61-e67. PubMed ID: 29191715
[TBL] [Abstract][Full Text] [Related]
60. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.
Avigdor A; Sirotkin T; Kedmi M; Ribakovsy E; Berkowicz M; Davidovitz Y; Kneller A; Merkel D; Volchek Y; Davidson T; Goshen E; Apter S; Shimoni A; Ben-Bassat I; Nagler A
Ann Hematol; 2014 Aug; 93(8):1297-304. PubMed ID: 24595734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]